Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: umbralisib
Trade Name: Ukoniq
Date Designated: 04/11/2019
Orphan Designation: Treatment of nodal marginal zone lymphoma
Orphan Designation Status: Designated/Approved
TG Therapeutics, Inc.
3020 Carrington Mill Blvd. Suite 475
Morrisville, North Carolina 27560
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: umbralisib
Trade Name: Ukoniq
Marketing Approval Date: 02/05/2021
Approved Labeled Indication: Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn)
Exclusivity End Date: 05/31/2022 
Exclusivity Protected Indication* :  Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn)
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-